Agilus Diagnostics Ltd. IPO Details
Agilus Diagnostics was originally incorporated on July 7, 1995. It is a diagnostics service provider.
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 14.2 M | - | - | ₹0 | DRHP DOC |
Agilus Diagnostics Ltd. issue details
Agilus Diagnostics Ltd. has 14.2 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Agilus Diagnostics Ltd. IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Agilus Diagnostics Ltd. NUMBER OF SHARES ON OFFER
Agilus Diagnostics Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Interest Income (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| FY23 | 1,166.4 | 13,474.6 | 1,911.4 | 504.7 | 19.5% |
| FY22 | 5,547.1 | 16,049.1 | 2,948.5 | 2,330.8 | 45.6% |
| FY21 | 1,312.5 | 10,350.7 | 1,766.2 | 1,419.3 | 23.6% |
Agilus Diagnostics Ltd. INFORMATION ON IPO ISSUE
About Agilus Diagnostics Ltd.
Agilus Diagnostics was originally incorporated on July 7, 1995. It is a diagnostics service provider.
Object of the Issue
- Achieve the benefits of listing the Equity Shares on the stock exchanges.
- Carry out the offer for sale of up to 14,233,964 equity shares held by International Finance Corporation, NYLIM Jacob Ballas India Fund III LLC and Resurgence PE Investments.
Agilus Diagnostics Ltd. - PROMOTERS
| Name |
|---|
| Fortis Healthcare Limited |
Agilus Diagnostics Ltd. Book running lead manager
ICICI Securities Limited
agilus.ipo@icicisecurities.com
Axis Capital Limited
agilus.ipo@axiscap.in
Citigroup Global Markets India Private Limited
Agilus.IPO@citi.com
Agilus Diagnostics Ltd. Registrar to the offer
KFin Technologies Limited
adl.ipo@kfintech.com
Agilus Diagnostics Ltd. Strengths
Pan-India service
With a widespread network of 413 laboratories as of 31 March 2023, it has served 16.62 million patients in fiscal 2023 and conducted an average of 107,043 diagnostic tests per day in fiscal 2023. To cater to the requirements of its institutional customers, it had over 12,000 pick-up points
Balanced B2C and B2B revenue mix
The company stands to benefit from both the B2C and B2B segments due to its well-balanced revenue mix. The B2C and B2B percentages of total revenue from operations stand at 54.31% and 45.69%, respectively
R&D capabilities
The company has a quality network of accredited laboratories supported by R&D capabilities focused on genomics and next-generation diagnostics
Agilus Diagnostics Ltd. Risks
Legal proceedings
The company recently changed its brand, which led to certain legal proceedings that are currently pending before the Delhi High Court. Any unfavourable outcome may have an adverse effect on the business, reputation, results of operations, and financial condition
Regulatory Risks
The company's promoter, Fortis Healthcare Limited, is subject to certain regulatory and statutory proceedings, including an appeal pending before the Securities Appellate Tribunal and an ongoing investigation by the Serious Fraud Investigation Office for certain alleged improper transactions and non-compliance with applicable laws and regulations, including the Companies Act. Any prolonged proceedings or adverse outcome of such proceedings in the future may have an adverse impact on the business and reputation
Dependence on CLIMS
The company's business depends significantly on the continued effectiveness of its information technology infrastructure, including its centralised laboratory information management system ("CLIMS"). Any disruption in these systems could adversely impact the business, results of operations, and financial condition
IPO FAQs
The promoter of the company is Fortis Healthcare Limited.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.